InMode Ltd. (NASDAQ: INMD), a leading provider of innovative medical technologies, is known for its advanced solutions in the aesthetic and medical markets. On November 5, 2025, INMD reported its earnings, showcasing strong financial performance. The company achieved an earnings per share (EPS) of $0.38, surpassing the estimated EPS of $0.35.
InMode's revenue for the third quarter of 2025 reached approximately $93.2 million, exceeding the estimated revenue of about $90.9 million. The company maintained a robust gross margin of 78%, demonstrating its efficiency in managing production costs relative to sales. Despite global economic challenges, InMode's strategic focus and disciplined execution are expected to support its long-term growth, as highlighted by CEO Moshe Mizrahy.
The company has appointed Michael Dennison as the new President of North America. Dennison, with the company since 2018, is anticipated to enhance regional strategy and customer engagement. This leadership change aligns with InMode's commitment to strengthening its market presence and customer relationships in North America.
InMode's financial metrics reflect its strong market position. The company has a price-to-earnings (P/E) ratio of approximately 5.1, indicating the market's valuation of its earnings. The price-to-sales ratio stands at about 2.52, and the enterprise value to sales ratio is around 2, suggesting a favorable market value relative to sales.
The company's financial health is further underscored by its low debt-to-equity ratio of approximately 0.01, indicating minimal reliance on debt financing. InMode also boasts a strong current ratio of about 9.6, highlighting its ability to cover short-term liabilities with short-term assets. The earnings yield of about 19.6% provides a measure of return on investment for shareholders.
